Will differentiated care for stable HIV patients reduce healthcare systems costs?. Issue 7 (20th July 2020)

• Record Type: Journal Article
• Authors: Larson, Bruce A; Pascoe, Sophie JS; Huber, Amy; Long, Lawrence C; Murphy, Joshua; Miot, Jacqui; Fox, Matthew P; Fraser‐Hurt, Nicole; Rosen, Sydney
• Is Part Of: Journal of the International AIDS Society. Volume 23:Issue 7(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-20
• Subjects: HIV -- cost of ART -- stable patients -- adherence clubs -- decentralized medication delivery -- adherence guidelines -- South Africa; AIDS (Disease) -- Periodicals; HIV infections -- Periodicals; 616.9792005
• DOI: 10.1002/jia2.25541
• Languages: English
• ISSNs: 1758-2652

Abstract

Abstract: Introduction: South Africa's National Department of Health launched the National Adherence Guidelines for Chronic Diseases in 2015. These guidelines include adherence clubs (AC) and decentralized medication delivery (DMD) as two differentiated models of care for stable HIV patients on antiretroviral therapy. While the adherence guidelines do not suggest that provider costs (costs to the healthcare system for medications, laboratory tests and visits to clinics or alternative locations) for stable patients in these differentiated models of care will be lower than conventional, clinic‐based care, recent modelling exercises suggest that such differentiated models could substantially reduce provider costs. In the context of continued implementation of the guidelines, we discuss the conditions under which provider costs of care for stable HIV patients could fall, or rise, with AC and DMD models of care in South Africa. Discussion: In prior studies of HIV care and treatment costs, three main cost categories are antiretroviral medications, laboratory tests and general interaction costs based on encounters with health workers. Stable patients are likely to be on the national first‐line regimen (Tenofovir/Entricitabine/Efavarinz (TDF/FTC/EFV)), so no difference in the costs of medications is expected. Laboratory testing guidelines for stable patients are the same regardless of the model of care, so no difference in laboratory costs is expected as well. Based on existing information regarding the costs of clinic visits, AC visits and DMD drug pickups, we expect that for some clinics, visit costs for DMD or AC models of care could be less, but modestly so, than for conventional, clinic‐based care. For other clinics, however, DMD or AC models could have higher visit costs (see Table 2). Conclusions: The standard of care for stable patients has already been "differentiated" for years in South Africa, prior to the roll out of the new adherence guidelines. AC and DMD models of care, when implemented as envisioned in the guidelines, are unlikely to generate substantive reductions or increases in provider costs of care.